| scholarly article | Q13442814 |
| P2093 | author name string | Anuradha Dube | |
| Swati Gupta | |||
| Suresh P Vyas | |||
| P2860 | cites work | Recent developments in leishmaniasis | Q35103824 |
| Advances in the treatment of leishmaniasis | Q35160721 | ||
| Antileishmanial activity of liposome-encapsulated amphotericin B in hamsters and monkeys | Q35653579 | ||
| Amphotericin B lipid complex: in visceral leishmaniasis | Q35871143 | ||
| In Vitro Study of the Anti-Leishmanial Activity of Biodegradable Nanoparticles | Q38574040 | ||
| Comparative pharmacokinetics, tissue distributions, and effects on renal function of novel polymeric formulations of amphotericin B and amphotericin B-deoxycholate in rats | Q39473415 | ||
| Treatment of experimental visceral leishmaniasis with amphotericin B in stable albumin microspheres. | Q39954346 | ||
| Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental models | Q40427592 | ||
| Lipid formulations of amphotericin B: recent progress and future directions | Q40941280 | ||
| Amphotericin B: new life for an old drug | Q41334774 | ||
| Modulation of amphotericin B activity by association with mannose ester | Q41452863 | ||
| Aerosolized liposome-based delivery of amphotericin B to alveolar macrophages | Q43539445 | ||
| Superior chemotherapeutic efficacy of amphotericin B in tuftsin-bearing liposomes against Leishmania donovani infection in hamsters | Q43983294 | ||
| In vitro antileishmanial activity of amphotericin B loaded in poly(epsilon-caprolactone) nanospheres | Q44395520 | ||
| Anti-leishmanial activity of a new formulation of amphotericin B. | Q45011384 | ||
| Treatment of paediatric visceral leishmaniasis: amphotericin B or pentavalent antimony compounds? | Q45202968 | ||
| Proteosomes, emulsomes, and cholera toxin B improve nasal immunogenicity of human immunodeficiency virus gp160 in mice: induction of serum, intestinal, vaginal, and lung IgA and IgG. | Q45762207 | ||
| Design of liposomes to improve delivery of amphotericin-B in the treatment of aspergillosis | Q46367909 | ||
| Lipid formulations of amphotericin B: clinical efficacy and toxicities | Q46460941 | ||
| Incorporation of amphotericin B in tuftsin-bearing liposomes showed enhanced efficacy against systemic cryptococcosis in leucopenic mice | Q46673609 | ||
| Targeting of mannosylated liposome incorporated benzyl derivative of Penicillium nigricans derived compound MT81 to reticuloendothelial systems for the treatment of visceral leishmaniasis | Q46731824 | ||
| Development and characterization of emulsomes for sustained and targeted delivery of an antiviral agent to liver | Q46990174 | ||
| Rapid separation of low molecular weight solutes from liposomes without dilution | Q47315153 | ||
| Development and characterization of amphotericin B bearing emulsomes for passive and active macrophage targeting. | Q51797993 | ||
| Distribution of liposomes containing mannobiose esters of fatty acid in rats. | Q52207238 | ||
| Leishmania donovani in hamsters: stimulation of non-specific resistance by some novel glycopeptides and impact on therapeutic efficacy. | Q54296169 | ||
| P433 | issue | 6 | |
| P921 | main subject | amphotericin B | Q412223 |
| visceral leishmaniasis | Q2046113 | ||
| P304 | page(s) | 437-444 | |
| P577 | publication date | 2007-07-01 | |
| P1433 | published in | Journal of Drug Targeting | Q6295099 |
| P1476 | title | Antileishmanial efficacy of amphotericin B bearing emulsomes against experimental visceral leishmaniasis | |
| P478 | volume | 15 |
| Q39547523 | Chitosan-based macrophage-mediated drug targeting for the treatment of experimental visceral leishmaniasis |
| Q51766744 | Development and evaluation of tripalmitin emulsomes for the treatment of experimental visceral leishmaniasis. |
| Q43978694 | Development and in vitro characterization of docetaxel-loaded ligand appended solid fat nanoemulsions for potential use in breast cancer therapy |
| Q39017657 | Development of targeted 1,2-diacyl-sn-glycero-3-phospho-l-serine-coated gelatin nanoparticles loaded with amphotericin B for improved in vitro and in vivo effect in leishmaniasis |
| Q37702257 | Drug delivery strategies for therapy of visceral leishmaniasis |
| Q38154347 | Drug resistance in leishmaniasis: current drug-delivery systems and future perspectives. |
| Q37407549 | Drug resistance in visceral leishmaniasis |
| Q39693592 | Drug targeting to macrophages using paromomycin-loaded albumin microspheres for treatment of visceral leishmaniasis: an in vitro evaluation. |
| Q38361935 | Emulsomes meet S-layer proteins: an emerging targeted drug delivery system |
| Q39203200 | Immunoadjuvant chemotherapy of visceral leishmaniasis in hamsters using amphotericin B-encapsulated nanoemulsion template-based chitosan nanocapsules |
| Q41879261 | Lipoidal soft hybrid biocarriers of supramolecular construction for drug delivery |
| Q33853860 | Physiologically based pharmacokinetic model of amphotericin B disposition in rats following administration of deoxycholate formulation (Fungizone®): pooled analysis of published data. |
| Q38154629 | Polymeric colloidal particulate systems: intelligent tools for intracellular targeting of antileishmanial cargos |
| Q53436548 | Preparation and performance evaluation of emulsomes as a drug delivery system for silybin. |
| Q37033956 | Supplementation of host response by targeting nitric oxide to the macrophage cytosol is efficacious in the hamster model of visceral leishmaniasis and adds to efficacy of amphotericin B. |
Search more.